Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Forecast, Price & News $26.17 -0.17 (-0.65%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$25.75▼$26.5250-Day Range$20.22▼$26.9352-Week Range$16.04▼$27.59Volume841,706 shsAverage Volume1.23 million shsMarket Capitalization$3.76 billionP/E RatioN/ADividend YieldN/APrice Target$43.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Insmed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside67.0% Upside$43.71 Price TargetShort InterestBearish8.65% of Shares Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.29Based on 8 Articles This WeekInsider TradingSelling Shares$14,933 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.08) to ($4.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector356th out of 968 stocksPharmaceutical Preparations Industry148th out of 445 stocks 4.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.71, Insmed has a forecasted upside of 67.0% from its current price of $26.17.Amount of Analyst CoverageInsmed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.65% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Insmed has recently increased by 11.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 65.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.29. Previous Next 2.4 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Insmed this week, compared to 3 articles on an average week.Search Interest12 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,933.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Insmed is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($5.08) to ($4.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInsmed has a P/B Ratio of 40.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insmed (NASDAQ:INSM) StockInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More INSM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INSM Stock News HeadlinesSeptember 22, 2023 | msn.comCantor Fitzgerald Maintains Insmed (INSM) Overweight RecommendationSeptember 20, 2023 | msn.comCantor Fitzgerald Reiterates Insmed (INSM) Overweight RecommendationSeptember 22, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 20, 2023 | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Sees Large Growth in Short InterestSeptember 20, 2023 | americanbankingnews.comInsmed (NASDAQ:INSM) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 20, 2023 | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Receives $43.71 Average Price Target from AnalystsSeptember 20, 2023 | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 8, 2023 | finance.yahoo.comWhy Shares of Insmed Are Soaring This WeekSeptember 22, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 8, 2023 | msn.comB of A Securities Maintains Insmed (INSM) Buy RecommendationSeptember 7, 2023 | msn.comEvercore ISI Group Maintains Insmed (INSM) Outperform RecommendationSeptember 7, 2023 | msn.comInsmed reports positive results from ARISE study of ARIKAYCESeptember 6, 2023 | markets.businessinsider.comBank of America Securities Remains a Buy on Insmed (INSM)September 6, 2023 | markets.businessinsider.comWhere Insmed Stands With AnalystsSeptember 6, 2023 | finance.yahoo.comInsmed (INSM) Up on Positive Data From MAC Lung Disease StudySeptember 6, 2023 | finance.yahoo.comInsmed To Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 5, 2023 | finance.yahoo.comInsmed (INSM): A Hidden Gem or Just Modestly Undervalued?September 5, 2023 | msn.comManchester United, America's Car-Mart fall; Insmed, Brady rise, Tuesday, 9/5/2023September 5, 2023 | msn.comWhy Lung Disease Focused Stock Insmed Is Trading Higher Today?September 5, 2023 | nasdaq.comInsmed Gains On Positive Phase 3 Results From ARISE Study Of ArikayceSeptember 5, 2023 | marketwatch.comInsmed Shares Hit 52-Week High After Positive Data for ArikayceSeptember 5, 2023 | proactiveinvestors.comInsmed stock climbs on positive study results; hits 52-week highSeptember 5, 2023 | finance.yahoo.comInsmed Is Making A Comeback — Why Shares Hit A Year High In Colossal VolumeSeptember 5, 2023 | markets.businessinsider.comInsmed Reports Positive Topline Results From Phase 3 ARISE Study Of ARIKAYCESeptember 5, 2023 | finance.yahoo.comINSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MACAugust 30, 2023 | msn.comUnusual Put Option Trade in Insmed (INSM) Worth $615.00KAugust 5, 2023 | msn.comMorgan Stanley Reiterates Insmed (INSM) Overweight RecommendationSee More Headlines Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address INSM Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.71 High Stock Price Forecast$53.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+67.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-481,530,000.00 Net Margins-258.22% Pretax Margin-257.66% Return on Equity-3,789.32% Return on Assets-49.54% Debt Debt-to-Equity Ratio13.13 Current Ratio5.15 Quick Ratio4.77 Sales & Book Value Annual Sales$245.36 million Price / Sales15.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book40.26Miscellaneous Outstanding Shares143,800,000Free Float137,617,000Market Cap$3.76 billion OptionableOptionable Beta1.56 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsAmicus TherapeuticsNASDAQ:FOLDImmunoGenNASDAQ:IMGNACADIA PharmaceuticalsNASDAQ:ACADMoonLake ImmunotherapeuticsNASDAQ:MLTXEvotecNASDAQ:EVOView All CompetitorsInsiders & InstitutionsVirginia Retirement Systems ET ALBought 21,200 shares on 8/22/2023Ownership: 0.015%California State Teachers Retirement SystemSold 5,411 shares on 8/21/2023Ownership: 0.114%Legato Capital Management LLCBought 14,589 shares on 8/18/2023Ownership: 0.036%Nuveen Asset Management LLCBought 1,931 shares on 8/16/2023Ownership: 0.247%Silverarc Capital Management LLCBought 670 shares on 8/15/2023Ownership: 0.100%View All Insider TransactionsView All Institutional Transactions INSM Stock - Frequently Asked Questions Should I buy or sell Insmed stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INSM shares. View INSM analyst ratings or view top-rated stocks. What is Insmed's stock price forecast for 2023? 13 Wall Street research analysts have issued 12-month price targets for Insmed's stock. Their INSM share price forecasts range from $28.00 to $53.00. On average, they anticipate the company's stock price to reach $43.71 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price. View analysts price targets for INSM or view top-rated stocks among Wall Street analysts. How have INSM shares performed in 2023? Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have increased by 31.0% and is now trading at $26.17. View the best growth stocks for 2023 here. Are investors shorting Insmed? Insmed saw a increase in short interest in August. As of August 31st, there was short interest totaling 12,440,000 shares, an increase of 11.9% from the August 15th total of 11,120,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is currently 10.1 days. View Insmed's Short Interest. When is Insmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our INSM earnings forecast. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.68. The biopharmaceutical company earned $77.23 million during the quarter, compared to analyst estimates of $70.23 million. Insmed had a negative trailing twelve-month return on equity of 3,789.32% and a negative net margin of 258.22%. The business's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.80) EPS. What ETFs hold Insmed's stock? ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include BNY Mellon Innovators ETF (BKIV), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Principal Healthcare Innovators ETF (BTEC). What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN). What is Insmed's stock symbol? Insmed trades on the NASDAQ under the ticker symbol "INSM." Who are Insmed's major shareholders? Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (2.98%), Bellevue Group AG (2.30%), Suvretta Capital Management LLC (2.16%), Geode Capital Management LLC (1.88%), Alliancebernstein L.P. (1.76%) and Holocene Advisors LP (1.45%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insmed's stock price today? One share of INSM stock can currently be purchased for approximately $26.17. How much money does Insmed make? Insmed (NASDAQ:INSM) has a market capitalization of $3.76 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. How many employees does Insmed have? The company employs 373 workers across the globe. How can I contact Insmed? Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381. This page (NASDAQ:INSM) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.